@article{MTMT:34069256,
	title = {Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2},
	url = {https://m2.mtmt.hu/api/publication/34069256},
	author = {Szabó, Enikő and Modok, Szabolcs and Rónaszéki, Benedek and Faragó, Anna and Gémes, Nikolett and Nagy, Lajos I. and Hackler, László and Farkas, Katalin and Neuperger, Patricia and Balog, József Ágoston and Balog, Attila and Puskás, László and Szebeni, Gábor},
	doi = {10.3389/fmed.2023.1176168},
	journal-iso = {FRONT MED},
	journal = {FRONTIERS IN MEDICINE},
	volume = {10},
	unique-id = {34069256},
	year = {2023},
	eissn = {2296-858X},
	orcid-numbers = {Szebeni, Gábor/0000-0002-6998-5632}
}

@article{MTMT:33805004,
	title = {The transcriptional control of the VEGFA-VEGFR1 (FLT1) axis in alternatively polarized murine and human macrophages},
	url = {https://m2.mtmt.hu/api/publication/33805004},
	author = {Domokos, Apolka and Varga, Zsófia and Jambrovics, Károly and Caballero-Sánchez, Noemí and Szabó, Enikő and Nagy, Gergely and Scholtz, Beáta and Halasz, Laszlo and Váradi, Eszter Anna and Bene, Krisztián and Mazlo, Anett and Bacsi, Attila and Jeney, Viktoria and Szebeni, Gábor and Nagy, László and Czimmerer, Zsolt},
	doi = {10.3389/fimmu.2023.1168635},
	journal-iso = {FRONT IMMUNOL},
	journal = {FRONTIERS IN IMMUNOLOGY},
	volume = {14},
	unique-id = {33805004},
	issn = {1664-3224},
	year = {2023},
	eissn = {1664-3224},
	orcid-numbers = {Nagy, Gergely/0000-0002-3273-731X; Bene, Krisztián/0000-0002-9963-8172; Szebeni, Gábor/0000-0002-6998-5632}
}

@article{MTMT:33211172,
	title = {A cytotoxic survey on 2-amino-1H-imidazol based synthetic marine sponge alkaloid analogues},
	url = {https://m2.mtmt.hu/api/publication/33211172},
	author = {Gémes, Nikolett and Makra, Zsófia and Neuperger, Patricia and Szabó, Enikő and Balog, József Ágoston and Flink, Lili Borbála and Kari, Beáta and Hackler, László and Puskás, László and Kanizsai, Iván and Szebeni, Gábor},
	doi = {10.1002/ddr.22006},
	journal-iso = {DRUG DEVELOP RES},
	journal = {DRUG DEVELOPMENT RESEARCH},
	volume = {83},
	unique-id = {33211172},
	issn = {0272-4391},
	abstract = {Here, we describe the synthesis and biologic activity evaluation of 20 novel synthetic marine sponge alkaloid analogues with 2-amino-1H-imidazol (2-AI) core. Cytotoxicity was tested on murine 4T1 breast cancer, A549 human lung cancer, and HL-60 human myeloid leukemia cells by the resazurin assay. A total of 18 of 20 compounds showed cytotoxic effect on the cancer cell lines with different potential. Viability of healthy human fibroblasts and peripheral blood mononuclear cells upon treatment was less hampered compared to cancer cell lines supporting tumor cell specific cytotoxicity of our compounds. The most cytotoxic compounds resulted the following IC50 values 28: 2.91 µM on HL-60 cells, and 29: 3.1 µM on 4T1 cells. The A549 cells were less sensitive to the treatments with IC50 15 µM for both 28 and 29. Flow cytometry demonstrated the apoptotic effect of the most active seven compounds inducing phosphatidylserine exposure and sub-G1 fragmentation of nuclear DNA. Cell cycle arrest was also observed. Four compounds caused depolarization of the mitochondrial membrane potential as an early event of apoptosis. Two lead compounds inhibited tumor growth in vivo in the 4T1 triple negative breast cancer and A549 human lung adenocarcinoma xenograft models. Novel marine sponge alkaloid analogues are demonstrated as potential anticancer agents for further development.},
	keywords = {Mannich; 2-amino-(1H)-imidazole; 4T1 breast cancer; A549 lung cancer; HL-60 myeloid leukemia},
	year = {2022},
	eissn = {1098-2299},
	pages = {1906-1922},
	orcid-numbers = {Szebeni, Gábor/0000-0002-6998-5632}
}

@article{MTMT:33115577,
	title = {Comparison of Homologous and Heterologous Booster SARS-CoV-2 Vaccination in Autoimmune Rheumatic and Musculoskeletal Patients},
	url = {https://m2.mtmt.hu/api/publication/33115577},
	author = {Honfi, Dániel György and Gémes, Nikolett and Szabó, Enikő and Neuperger, Patricia and Balog, József Ágoston and Nagy, Lajos I. and Toldi, Gergely and Puskás, László and Szebeni, Gábor and Balog, Attila},
	doi = {10.3390/ijms231911411},
	journal-iso = {INT J MOL SCI},
	journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
	volume = {23},
	unique-id = {33115577},
	issn = {1661-6596},
	abstract = {Vaccination against SARS-CoV-2 to prevent COVID-19 is highly recommended for immunocompromised patients with autoimmune rheumatic and musculoskeletal diseases (aiRMDs). Little is known about the effect of booster vaccination or infection followed by previously completed two-dose vaccination in aiRMDs. We determined neutralizing anti-SARS-CoV-2 antibody levels and applied flow cytometric immunophenotyping to quantify the SARS-CoV-2 reactive B- and T-cell mediated immunity in aiRMDs receiving homologous or heterologous boosters or acquired infection following vaccination. Patients receiving a heterologous booster had a higher proportion of IgM+ SARS-CoV-2 S+ CD19+CD27+ peripheral memory B-cells in comparison to those who acquired infection. Biologic therapy decreased the number of S+CD19+; S+CD19+CD27+IgG+; and S+CD19+CD27+IgM+ B-cells. The response rate to a booster event in cellular immunity was the highest in the S-, M-, and N-reactive CD4+CD40L+ T-cell subset. Patients with a disease duration of more than 10 years had higher proportions of CD8+TNF-α+ and CD8+IFN-γ+ T-cells in comparison to patients who were diagnosed less than 10 years ago. We detected neutralizing antibodies, S+ reactive peripheral memory B-cells, and five S-, M-, and N-reactive T-cells subsets in our patient cohort showing the importance of booster events. Biologic therapy and <10 years disease duration may confound anti-SARS-CoV-2 specific immunity in aiRMDs.},
	year = {2022},
	eissn = {1422-0067},
	orcid-numbers = {Toldi, Gergely/0000-0003-0178-1243; Szebeni, Gábor/0000-0002-6998-5632}
}

@article{MTMT:32733913,
	title = {α/β-Peptides as Nanomolar Triggers of Lipid Raft-Mediated Endocytosis through GM1 Ganglioside Recognition},
	url = {https://m2.mtmt.hu/api/publication/32733913},
	author = {Hetényi, Anasztázia and Szabó, Enikő and Imre, Norbert and Nath Bhaumik, Kaushik and Tököli, Attila and Füzesi, Tamás and Hollandi, Réka and Horváth, Péter and Czibula, Ágnes and Monostori, Éva and Deli, Mária Anna and Martinek, Tamás},
	doi = {10.3390/pharmaceutics14030580},
	journal-iso = {PHARMACEUTICS},
	journal = {PHARMACEUTICS},
	volume = {14},
	unique-id = {32733913},
	issn = {1999-4923},
	abstract = {Cell delivery of therapeutic macromolecules and nanoparticles is a critical drug development challenge. Translocation through lipid raft-mediated endocytic mechanisms is being sought, as it can avoid rapid lysosomal degradation. Here, we present a set of short alpha/beta-peptide tags with high affinity to the lipid raft-associated ganglioside GM1. These sequences induce effective internalization of the attached immunoglobulin cargo. The structural requirements of the GM1-peptide interaction are presented, and the importance of the membrane components are shown. The results contribute to the development of a receptor-based cell delivery platform.},
	year = {2022},
	eissn = {1999-4923},
	orcid-numbers = {Hetényi, Anasztázia/0000-0001-8080-6992; Tököli, Attila/0000-0001-8413-3182; Monostori, Éva/0000-0002-7442-3562; Deli, Mária Anna/0000-0001-6084-6524; Martinek, Tamás/0000-0003-3168-8066}
}

@article{MTMT:32728646,
	title = {Humoral and cellular immunogenicity and safety of five different SARS-CoV-2 vaccines in patients with autoimmune rheumatic and musculoskeletal diseases in remission or with low disease activity and in healthy controls: a single center study},
	url = {https://m2.mtmt.hu/api/publication/32728646},
	author = {Szebeni, Gábor and Gémes, Nikolett and Honfi, Dániel György and Szabó, Enikő and Neuperger, Patricia and Balog, József Ágoston and Nagy, LI and Szekanecz, Zoltán and Puskás, László and Toldi, Gergely and Balog, Attila},
	doi = {10.3389/fimmu.2022.846248},
	journal-iso = {FRONT IMMUNOL},
	journal = {FRONTIERS IN IMMUNOLOGY},
	volume = {13},
	unique-id = {32728646},
	issn = {1664-3224},
	abstract = {Background: Vaccine-induced immunity is essential for controlling the COVID-19 pandemic. Data on humoral and cellular immunogenicity and safety of different SARS-CoV-2 vaccines in patients with autoimmune rheumatic and musculoskeletal diseases (RMDs) are limited. 
		
		Methods: A single center observational study evaluated the immunogenicity and safety of the two-dose regimen of the BBIBP-CorV inactivated, Gam-COVID-Vac and AZD1222 adenovirus-based, and BNT162b2 and mRNA-1273 mRNA-based vaccines in patients with RMDs (n = 89) compared with healthy controls (n = 74). Neutralizing anti-RBD (receptor binding domain) specific antibodies and SARS-CoV-2 specific T-cell response were measured one and four months after the second vaccine dose in parallel with vaccination efficacy and safety. 
		
		Results: Disease-specific comparison showed that antibody response at four months was higher in spondylarthropathies compared to rheumatoid arthritis and autoimmune RMDs. Risk factors for reduced immunogenicity included longer disease duration, positive immunoserological profile and anti-CD20 therapy of patients. The rate of positive anti-RBD antibody response for healthy controls versus patients after 4 months post vaccination was 69% vs. 55% for the inactivated viral vaccine BBIBP-CorV, 97% vs. 53% for the pooled data of adenovirus vector-based vaccines Gam-COVID-Vac and AZD1222, or 100% vs. 81% for the pooled data of mRNA vaccines BNT162b2 and mRNA-1273, respectively. Patients who received the Gam-COVID-Vac or mRNA-1273 vaccines had a higher proportion of TNF-alpha producing CD4+ T-cells upon SARS-CoV-2 antigen stimulation compared to the inactivated viral vaccine. 
		
		Conclusion: All five investigated vaccines were immunogenic in the majority of patients and healthy controls with variable antibody and T-cell response and an acceptable safety profile.},
	keywords = {Rheumatic and musculoskeletal diseases; CD8(+)T-cell response; SARS-CoV-2 vaccination; anti-RBD neutralizing antibodies; CD4(+) T-cell response},
	year = {2022},
	eissn = {1664-3224},
	orcid-numbers = {Szebeni, Gábor/0000-0002-6998-5632; Toldi, Gergely/0000-0003-0178-1243}
}

@article{MTMT:32570862,
	title = {Fehérje méretű molekulák humán sejtekbe juttatása lipid-raft mediált endocitózissal},
	url = {https://m2.mtmt.hu/api/publication/32570862},
	author = {Hetényi, Anasztázia and Imre, Norbert and Szabó, Enikő and Bodnár, Brigitta and Szkalisity, Ábel and Gróf, Ilona and Bocsik, Alexandra and Deli, Mária Anna and Horváth, Péter and Czibula, Ágnes and Monostori, Éva and Martinek, Tamás},
	journal-iso = {BIOKÉMIA},
	journal = {BIOKÉMIA: A MAGYAR BIOKÉMIAI EGYESÜLET FOLYÓIRATA},
	volume = {45},
	unique-id = {32570862},
	issn = {0133-8455},
	year = {2021},
	eissn = {2060-8152},
	pages = {67-83},
	orcid-numbers = {Hetényi, Anasztázia/0000-0001-8080-6992; Deli, Mária Anna/0000-0001-6084-6524; Czibula, Ágnes/0000-0003-4461-2773; Monostori, Éva/0000-0002-7442-3562; Martinek, Tamás/0000-0003-3168-8066}
}

@article{MTMT:31126947,
	title = {Routing Nanomolar Protein Cargoes to Lipid Raft‐Mediated/Caveolar Endocytosis through a Ganglioside GM1‐Specific Recognition Tag},
	url = {https://m2.mtmt.hu/api/publication/31126947},
	author = {Imre, Norbert and Hetényi, Anasztázia and Szabó, Enikő and Bodnár, Brigitta and Szkalisity, Ábel and Gróf, Ilona and Bocsik, Alexandra and Deli, Mária Anna and Horváth, Péter and Czibula, Ágnes and Monostori, Éva and Martinek, Tamás},
	doi = {10.1002/advs.201902621},
	journal-iso = {ADV SCI},
	journal = {ADVANCED SCIENCE},
	volume = {7},
	unique-id = {31126947},
	year = {2020},
	eissn = {2198-3844},
	orcid-numbers = {Hetényi, Anasztázia/0000-0001-8080-6992; Deli, Mária Anna/0000-0001-6084-6524; Czibula, Ágnes/0000-0003-4461-2773; Monostori, Éva/0000-0002-7442-3562; Martinek, Tamás/0000-0003-3168-8066}
}

@article{MTMT:30802849,
	title = {Altered Cell Surface N-Glycosylation of Resting and Activated T Cells in Systemic Lupus Erythematosus},
	url = {https://m2.mtmt.hu/api/publication/30802849},
	author = {Szabó, Enikő and Hornung, Ákos and Monostori, Éva and Bocskai, Márta and Czibula, Ágnes and Kovács, László},
	doi = {10.3390/ijms20184455},
	journal-iso = {INT J MOL SCI},
	journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
	volume = {20},
	unique-id = {30802849},
	issn = {1661-6596},
	year = {2019},
	eissn = {1422-0067},
	orcid-numbers = {Monostori, Éva/0000-0002-7442-3562; Kovács, László/0000-0003-4457-1430}
}

@article{MTMT:30750520,
	title = {TMEM203 is a binding partner and regulator of STING-mediated inflammatory signaling in macrophages},
	url = {https://m2.mtmt.hu/api/publication/30750520},
	author = {Li, Yang and James, Sharmy J and Wyllie, David H and Wynne, Claire and Czibula, Ágnes and Bukhari, Ahmed and Pye, Katherine and Bte Mustafah, Seri Musfirah and Fajka-Boja, Roberta and Szabó, Enikő and Angyal, Adrienn and Hegedűs, Zoltán and Kovács, László and Hill, Adrian V S and Jefferies, Caroline A and Wilson, Heather L and Yongliang, Zhang and Kiss-Tóth, Endre},
	doi = {10.1073/pnas.1901090116},
	journal-iso = {P NATL ACAD SCI USA},
	journal = {PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA},
	volume = {116},
	unique-id = {30750520},
	issn = {0027-8424},
	abstract = {Regulation of IFN signaling is critical in host recognition and response to pathogens while its dysregulation underlies the pathogenesis of several chronic diseases. STimulator of IFN Genes (STING) has been identified as a critical mediator of IFN inducing innate immune pathways, but little is known about direct coregulators of this protein. We report here that TMEM203, a conserved putative transmembrane protein, is an intracellular regulator of STING-mediated signaling. We show that TMEM203 interacts, functionally cooperates, and comigrates with STING following cell stimulation, which in turn leads to the activation of the kinase TBK1, and the IRF3 transcription factor. This induces target genes in macrophages, including IFN-β. Using Tmem203 knockout bone marrow-derived macrophages and transient knockdown of TMEM203 in human monocyte-derived macrophages, we show that TMEM203 protein is required for cGAMP-induced STING activation. Unlike STING, TMEM203 mRNA levels are elevated in T cells from patients with systemic lupus erythematosus, a disease characterized by the overexpression of type I interferons. Moreover, TMEM203 mRNA levels are associated with disease activity, as assessed by serum levels of the complement protein C3. Identification of TMEM203 sheds light into the control of STING-mediated innate immune responses, providing a potential novel mechanism for therapeutic interventions in STING-associated inflammatory diseases.},
	keywords = {lupus; STIM1; STING; interferon signaling; TMEM203},
	year = {2019},
	eissn = {1091-6490},
	pages = {16479-16488},
	orcid-numbers = {Czibula, Ágnes/0000-0003-4461-2773; Fajka-Boja, Roberta/0000-0001-5331-8280; Kovács, László/0000-0003-4457-1430}
}